Royalty Pharma Plc Stock Price on December 11, 2024
| RPRX Stock | USD 25.23 0.02 0.08% |
Below is the normalized historical share price chart for Royalty Pharma Plc extending back to June 16, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Royalty Pharma stands at 25.23, as last reported on the 25th of December, with the highest price reaching 25.35 and the lowest price hitting 25.02 during the day.
If you're considering investing in Royalty Stock, it is important to understand the factors that can impact its price. Royalty Pharma Plc maintains Sharpe Ratio (i.e., Efficiency) of -0.15, which implies the firm had a -0.15% return per unit of risk over the last 3 months. Royalty Pharma Plc exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Royalty Pharma's Coefficient Of Variation of (861.36), variance of 1.14, and Risk Adjusted Performance of (0.09) to confirm the risk estimate we provide.
At this time, Royalty Pharma's Total Stockholder Equity is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 17.5 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 409.1 M in 2024. . At this time, Royalty Pharma's Price Book Value Ratio is fairly stable compared to the past year. Price Earnings To Growth Ratio is likely to rise to 0 in 2024, whereas Price To Sales Ratio is likely to drop 5.07 in 2024. Royalty Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 25th of March 1993 | 200 Day MA 27.5604 | 50 Day MA 26.3982 | Beta 0.466 |
Royalty |
Sharpe Ratio = -0.1488
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RPRX |
Estimated Market Risk
| 1.06 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Royalty Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Royalty Pharma by adding Royalty Pharma to a well-diversified portfolio.
Price Book 1.633 | Enterprise Value Ebitda 8.8814 | Price Sales 6.56 | Shares Float 383.9 M | Dividend Share 0.83 |
Related Headline
Monte Rosa Headline on 11th of December 2024
Monte Rosa Therapeutics Announces Closing of Global License ... by finance.yahoo.com
BOSTON, Dec. 11, 2024 -- Monte Rosa Therapeutics, Inc. , a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, today announced the closing of the Companys previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs, including MRT-6160. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, an
Royalty Pharma Valuation on December 11, 2024
It is possible to determine the worth of Royalty Pharma on a given historical date. On December 11, 2024 Royalty was worth 25.43 at the beginning of the trading date compared to the closed value of 25.2. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Royalty Pharma stock. Still, in general, we apply an absolute valuation method to find Royalty Pharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Royalty Pharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Royalty Pharma's related companies.
| Open | High | Low | Close | Volume | |
| 26.05 | 26.05 | 25.46 | 25.59 | 3,130,282 | |
12/11/2024 | 25.43 | 25.50 | 25.02 | 25.20 | 2,851,454 |
| 25.11 | 25.42 | 25.10 | 25.21 | 2,891,108 |
| Backtest Royalty Pharma | | | Royalty Pharma History | | | Royalty Pharma Valuation | Previous | Next |
Royalty Pharma Trading Date Momentum on December 11, 2024
| On December 12 2024 Royalty Pharma Plc was traded for 25.21 at the closing time. The top price for the day was 25.42 and the lowest listed price was 25.10 . The trading volume for the day was 2.9 M. The trading history from December 12, 2024 was a factor to the next trading day price jump. The trading delta at closing time against the next closing price was 0.04% . The trading delta at closing time against the current closing price is 1.90% . |
Royalty Pharma Plc Fundamentals Correlations and Trends
By evaluating Royalty Pharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Royalty financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Royalty Pharma Stock history
Royalty Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Royalty is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Royalty Pharma Plc will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Royalty Pharma stock prices may prove useful in developing a viable investing in Royalty Pharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 602.9 M | 409.1 M | |
| Net Income Applicable To Common Shares | 49.3 M | 46.8 M |
Royalty Pharma Quarterly Net Working Capital |
|
Royalty Pharma Stock Technical Analysis
Royalty Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Royalty Pharma Period Price Range
Low | December 25, 2024
| High |
0.00 | 0.00 |
Royalty Pharma Plc cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Royalty Pharma December 25, 2024 Market Strength
Market strength indicators help investors to evaluate how Royalty Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Royalty Pharma shares will generate the highest return on investment. By undertsting and applying Royalty Pharma stock market strength indicators, traders can identify Royalty Pharma Plc entry and exit signals to maximize returns
Royalty Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Royalty Pharma's price direction in advance. Along with the technical and fundamental analysis of Royalty Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Royalty to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.57) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.